We aim to characterise the epigenetic landscape of multiple myeloma (MM) and identify the epigenetic alterations that distinguish MM cells from normal plasma cells, as well as differences between clinically or genetically distinct MM subgroups. In MM, tumour cells proliferate uncontrollably within the bone marrow, driven by complex genetic changes that disrupt normal regulatory pathways, including those triggering apoptosis. Using patient-derived samples, we will explore how these epigenetic changes are linked to alterations in gene expression.